Clinical Research Directory
Browse clinical research sites, groups, and studies.
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC
Official title: A Phase 3, Randomized, Open-Label, Active-Controlled, Multicenter Study of ZG005 in Combination With Bevacizumab Versus Sintilimab in Combination With Bevacizumab in the First-Line Treatment of Advanced Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2026-09
Completion Date
2032-09
Last Updated
2026-09-10
Healthy Volunteers
No
Conditions
Interventions
ZG005 for Injection
Participants receive ZG005 20 mg/kg IV, Q3W
Bevacizumab ( Avastin)
Participants receive Bevacizumab ( Avastin) 15 mg/kg IV, Q3W
Sintilimab
Participants receive Sintilimab 200mg IV, Q3W
Bevacizumab
Participants receive Bevacizumab 15 mg/kg IV, Q3W
Locations (1)
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China